^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | adavosertib (AZD1775) (WEE1 inhibitor) + SRA737 (Chk1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1010-A study of combinatorial growth inhibition, cell death and DNA damage repair caused by CHK1 inhibitor SRA737 and WEE1 inhibitor adavosertib in TP53 mutated cell lines
Published date:
03/10/2021
Excerpt:
We chose to explore the combination in the TP53 mutated OVCAR3 and the TP53 and BRCA1 mutated MDA-MB-436 cell lines. In the OVCAR3 xenograft model, the combination of SRA737 and adavosertib caused tumour regressions and tumour volumes were significantly smaller than controls, p<0001. The combination caused a lesser but significant degree of reduction in the tumour volume in the MDA-MB-436 xenograft model compared to control p=0.003. There was less than a 20% loss of mouse body weight in treatment arms of both xenograft models.
